Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05154448
Other study ID # LBP003
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date May 16, 2022
Est. completion date April 1, 2024

Study information

Verified date September 2023
Source FUSMobile Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Double arm pivotal study to evaluate the Neurolyser XR as a non-invasive treatment of axial chronic low back pain


Description:

Study design: Prospective, Double Arm Timeline: Twelve months enrollment period and 6 months follow-up period. Sites: The study will be conducted at 10 sites in the USA Study population: 80 adult subjects diagnosed with facet related low back pain with an additional 10 roll in subjects. Arms: 40 patients would be treated by the NeurolyserXR and 40 would get a sham treatment Crossover: blinded crossover between the two arms could be done between 1 and 3 months Primary study objective: Safety and efficacy of the Neurolyser XR for the treatment of chronic low back pain secondary to zygapophyseal joint syndrome. Safety is measured by the incidence and severity of treatment related adverse events. Efficacy is measured by pain numerical rating scale


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 90
Est. completion date April 1, 2024
Est. primary completion date April 1, 2024
Accepts healthy volunteers No
Gender All
Age group 50 Years to 85 Years
Eligibility Inclusion Criteria: 1. Age 50 to 85 years old, legally able and willing to participate in the study and all follow-up visits 2. Able and willing to complete the research questionnaires and to communicate with investigator and research team 3. Individual with current bilateral or unilateral low back pain of > 6 months duration 4. Individual whose back pain is alleviated by recumbency or comfortable sitting position 5. Individual presenting with a) a positive (>80% pain relief) to a previous, double, lumbar medial branch block (within the last 12 months) and/or b) with a positive (>70% pain relief lasting more than 6 months) to the most recent lumbar facet thermal radiofrequency denervation 6. Average low back pain score of 6 or higher in the last month (on 0-10 scale) with activity Exclusion Criteria: 1. Individuals who are pregnant or breastfeeding 2. Individuals younger than 50 or older than 85 years 3. BMI greater than 40, or individuals with at least one of the planned targets outside the Neurolyser XR treatment envelope as seen on treatment day on a lateral X-ray scan taken before the treatment. 4. Individuals presenting with neurological deficits (including lumbosacral radiculopathy but not solitary radicular pain) 5. Individuals with history of lumbar or lumbosacral spine surgery 6. Individuals who have had lumbar radiofrequency neurotomy in the past 6 months 7. Individuals with history of lumbar spine pathology that may increase procedural risk and/or influence symptoms and/or generate unrelated adverse event (per investigator's discretion) 8. Individuals presenting with any severe medical condition preventing them from participation (per investigator's discretion) (Example: inability to lay prone) 9. Individuals with extensive scarring of the skin and tissue overlying the treatment area 10. Individuals enrolled in or planned to be enrolled in another clinical trial during the duration of this research project 11. Any Individuals with an uncontrolled coagulopathy 12. Individuals with known osteoporosis with absolute risk of spinal fracture of > 10% over 10 years 13. Any Individuals with a history of malignant disease in the past five years or any individuals with clinical history suggestive of new/previously unknown malignancy and pathological pain who require further work up or is currently undergoing work up 14. Individuals with rheumatologic diseases causing spine pain that are currently receiving active treatment including steroids, disease modifying drugs, biological agents or immunosuppressants 15. Individuals known for concomitant psychiatric disorders, excluding compensated mood disorders 16. Individuals with first-degree family member already enrolled in this study 17. Individual who is scheduled for any interventional/surgical procedure within 6 months from the treatment date excluding trivial surgeries (e.g., cataract, carpal tunnel release) 18. Individuals diagnosed with co-morbid multifocal chronic pain (e.g. fibromyalgia, generalized osteoarthritis) 19. Individuals with other chronic pain that is 2 or more points higher on the NRS score than the participants low back pain 20. Individuals who have had a steroid injection within the last 2 months from date of enrollment at the location of the planned treatment 21. Any individuals with clinical or radiographic evidence of dynamic instability of the lumbar spine

Study Design


Intervention

Device:
Non-Invasive Thermal Ablation of the Medial Branch Nerves (Neurolyser XR)
Thermal ablation of the medial nerve branch using High Intensity Focused Ultrasound
Other:
Sham procedure
Sham procedure done in an identical manner to the treatment arm, but without deploying acoustical energy

Locations

Country Name City State
United States Emory Atlanta Georgia
United States The Physicians Spine and Rehabilitation Specialist of GA Atlanta Georgia
United States Charlie Norwood VA Medical Center Augusta Georgia
United States University of Virginia Pain Management Center Charlottesville Virginia
United States Mayo University Jacksonville Jacksonville Florida
United States Univ of Miami Rehabilitation Medicine Miami Florida
United States Ainsworth Institute of Pain Management New York New York
United States Stamford Hospital Stamford Connecticut
United States Gershon Pain Specialists Virginia Beach Virginia
United States Center for Clinical Research Winston-Salem North Carolina

Sponsors (1)

Lead Sponsor Collaborator
FUSMobile Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary NRS Change in average pain score as measured by a numeric rating scale from 0 (no pain) to 10, worst possible pain Base line, 2 days 1, 2 & 4 weeks, 3 & 6 months after procedure
Primary Procedure and Device Safety up to six months post procedure Safety will be measured by the incidence and severity of treatment related adverse events 6 months after procedure
Secondary Oswestry Disability Index (ODI) Low Back Pain Questionnaire (Range: 0% to 100%) Time Frame: Base line, 1, & 4 weeks, 3 & 6 months after procedure
Secondary Patient Global Impression of Change (PGIC) Patient Global Impression of Change (Range: 1 to 7) Time Frame: Base line, 1, & 4 weeks, 3 & 6 months after procedure
See also
  Status Clinical Trial Phase
Completed NCT03770585 - Fluoroscopy Guided Lumbar Facet Joint Injection Versus Ultrasound Guided Injection in Patients With Low Back Pain Due to Facet Syndrome N/A
Active, not recruiting NCT04129034 - Safety and Initial Feasibility of Using the Neurolyser XR Device for the Treatment of Axial Chronic Low Back Pain N/A
Recruiting NCT04893720 - The SPINUS II Study: Spinal Fusion for Multilevel SPECT/CT Positive Lumbar Degeneration
Recruiting NCT06325631 - Comparative Evaluation of the Results of Facet Joint Injections N/A
Recruiting NCT03564418 - Ultrasound-Guided Thermocoagulation of Medial Nerve Branch in Lumbar Facet Joints Pain. N/A
Completed NCT04519541 - RAMBAM 021: Safety and Initial Feasibility of the Neurolyser XR for the Treatment of Chronic Low Back Pain N/A
Recruiting NCT03871192 - Injections in the Diagnosis and Treatment of Lumbar Facet Syndrome N/A